Hospital-acquired Disease Testing Market, by Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus (MRSA), and Others), and by Region (North America, Latin Americ

Hospital-acquired Disease Testing Market, by Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus (MRSA), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hospital-acquired infections are acquired by the patient under medical care. The most common types of hospital-acquired infections are urinary tract infections, bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA), pneumococcal infections, and gastrointestinal illnesses. An increasing rate of morbidity related to hospital-acquired infections worldwide is a major factor driving the growth of the hospital-acquired disease testing market. Devices such as catheters and ventilators that are used in modern care facilities are also among the primary causes of these infections.
Market Dynamics
Key players in the market are focused on adoption of expansion strategies such as mergers and acquisitions, collaborations, and partnerships in order to expand their product portfolio and global presence in the hospital-acquired disease testing market. For instance, in April 2019, Meridian Bioscience, Inc. entered an agreement to acquire GenePOC Inc., a Canada based provider of molecular diagnostic instruments and assays. Through this acquisition, Meridian Bioscience will include state-of-the art revogene molecular diagnostics platform of GenePOC Inc. in its diagnostics portfolio.
Key features of the study:
This report provides in-depth analysis of the global hospital-acquired disease testing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hospital-acquired disease testing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Luminex Corporation, Diatherix laboratories, Life technologies, Cantel Medical Corporation, Meridian Biosciences Inc, Nordion Inc, Qiagen GmbH, F.Hoffmann-La Roche Ltd., Biomérieux, and Cepheid.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, product Type up-gradation, market expansion, and marketing tactics
The global hospital-acquired disease testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hospital-acquired disease testing market
Detailed Segmentation:
Global hospital-acquired disease testing Market, By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
Global hospital-acquired disease testing Market, By Region:
North America
By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
By Country:
U.S.
Canada
Latin America
By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Test Type:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-resistant Staphylococcus Aureus (MRSA)
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Luminex Corporation*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Diatherix Laboratories
Life Technologies
Cantel Medical Corporation
Meridian Biosciences Inc.
Nordion Inc.
Qiagen GmbH
Hoffmann-La Roche Ltd.
Biomérieux
Cepheid
“*” marked represents similar segmentation in other categories in the respective section.